A Phase II Evaluation of ABI-007 (IND 55,974) in the Treatment of Persistent or Recurrent Squamous or Nonsquamous Cell Carcinoma of the Cervix.

Trial Profile

A Phase II Evaluation of ABI-007 (IND 55,974) in the Treatment of Persistent or Recurrent Squamous or Nonsquamous Cell Carcinoma of the Cervix.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jan 2015

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Cervical cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 30 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 09 Jan 2014 Status changed from active, no longer recruiting to discontinued as per M D Anderson Cancer Center record
    • 22 Feb 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top